Table 3.
Associations between Treatment Outcomes and XPD Haplotypes*
| Complete Response | Resistant Disease | Overall Survival | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| XPD Haplotype | Totla N | |||||||||
| N | OR | CI | N | OR | CI | N of Deaths | HR | CI | ||
| AA** | 105 | 48 | 1.00 | – | 31 | 1.00 | – | 80 | 1.00 | – |
| AC | 11 | 4 | 0.84 | 0.19–3.63 | 6 | 2.35 | 0.61–9.09 | 10 | 1.21 | 0.62–2.36 |
| BB | 24 | 17 | 4.53 | 1.60–12.87 | 6 | 0.66 | 0.23–1.88 | 19 | 0.71 | 0.42–1.19 |
| BC | 10 | 6 | 3.58 | 0.81–15.81 | 2 | 0.40 | 0.08–2.09 | 8 | 0.92 | 0.44–1.92 |
| DA | 18 | 10 | 2.05 | 0.64–6.54 | 4 | 0.63 | 0.19–2.15 | 12 | 0.74 | 0.40–1.36 |
| DB | 16 | 9 | 0.82 | 0.21–3.17 | 4 | 1.14 | 0.31–4.14 | 12 | 1.15 | 0.62–2.14 |
| DC† | 85 | 50 | 2.00 | 1.04–3.83 | 22 | 0.73 | 0.37–1.45 | 68 | 0.90 | 0.65–1.25 |
| AA (‘0’ variant alleles) | 105 | 48 | 1.00 | – | 31 | 1.00 | – | 80 | 1.00 | – |
| AC/DA (1 variant allele) | 29 | 14 | 1.45 | 0.57–3.70 | 10 | 1.09 | 0.43–2.73 | 22 | 0.90 | 0.56–1.45 |
| CC/DD/DC (2 variant alleles) | 89 | 52 | 2.00 | 1.05–3.79 | 24 | 0.75 | 0.38–1.48 | 71 | 0.89 | 0.65–1.24 |
| BC/DB (3 variant alleles) | 26 | 15 | 1.62 | 0.57–4.59 | 6 | 0.71 | 0.25–2.05 | 20 | 1.04 | 0.63–1.72 |
| BB (4 variant alleles) | 24 | 17 | 4.56 | 1.60–12.95 | 6 | 0.65 | 0.23–1.86 | 19 | 0.71 | 0.42–1.18 |
| AA** | 105 | 48 | 1.00 | – | 31 | 1.00 | – | 80 | 1.00 | – |
| DA | 18 | 10 | 2.05 | 0.64–6.53 | 4 | 0.63 | 0.19–2.16 | 12 | 0.74 | 0.40–1.36 |
| DC | 85 | 50 | 2.00 | 1.04–3.83 | 22 | 0.72 | 0.36–1.44 | 68 | 0.90 | 0.65–1.25 |
| Other | 65 | 38 | 2.20 | 1.08–4.48 | 20 | 0.91 | 0.45–1.86 | 52 | 0.90 | 0.63–1.30 |
| AA/AC/BB/BC/CC | 151 | 76 | 1.00 | – | 45 | 1.00 | – | 118 | 1.00 | – |
| DA/DB/DC/DD | 122 | 70 | 1.27 | 0.74–2.16 | 32 | 0.84 | 0.48–1.49 | 94 | 0.95 | 0.72–1.25 |
| Total | 273 | 146 | 77 | 212 | ||||||
Haplotypes: A=Lys751A/Asp312G; B=Gln751C/Asn312A; C=Lys751A/Asn312A; D=Gln751C/Asp312G; Haplotype frequencies: A=0.424; B=0.121; C=0.211; D=0.242
CR and OS estimates are adjusted for the following covariates: age (continuous), AML onset (de novo vs. secondary), cytogenetic group (favorable, intermediate, unfavorable, unknown), peripheral white cell count (continuous), type of HSCT (allogenic, autologous, none); RD estimates are adjusted for: age, AML onset, cytogenetic group, induction therapy, HSCT
Referent haplotype or haplotype category OR = estimated odds ratio, HR = estimated hazard ratio, CI = 95% confidence interval
Haplotypes CC (n=1) and DD (n=3) were excluded from this analysis because of small numbers OR = estimated odds ratio, HR = estimated hazard ratio, CI = 95% confidence interval.